Curaleaf Holdings (CURLF) Capital Expenditures (2019 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Capital Expenditures of $80.7 million for Q4 2024, up 56.37% year-on-year from $51.6 million in Q1 2024, and up 390.53% on a QoQ basis from -$27.8 million in Q3 2024.
Curaleaf Holdings (CURLF) Capital Expenditures (2019 - 2024) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Capital Expenditures for 6 consecutive years, with $80.7 million the latest figure, recorded in Q4 2024.
- Quarterly Capital Expenditures rose 56.37% year-over-year to $80.7 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $89.2 million (down 63.67% YoY) and the FY2025 annual result came in at $2.8 million, down 81.78% from the prior year.
- Capital Expenditures climbed to $80.7 million in Q4 2024 per CURLF's latest filing, from -$27.8 million in the prior quarter.
- Over the last five years, Capital Expenditures for CURLF reached as high as $239.6 million in Q4 2022 and fell as low as -$54.6 million in Q4 2021.
- A 5-year average of $14.9 million and a median of -$27.8 million in 2024 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2021 — Capital Expenditures slumped 135.6% — and 2022, when it soared 538.92%.
- Year by year, Capital Expenditures stood at $196.5 million in 2020, then slumped by 127.79% to -$54.6 million in 2021, then surged by 538.92% to $239.6 million in 2022, then slumped by 78.45% to $51.6 million in 2023, then surged by 56.37% to $80.7 million in 2024.
- According to Business Quant data, Capital Expenditures over the past three periods registered $80.7 million, -$27.8 million, and $51.6 million for Q4 2024, Q3 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 80.75 Mn |
| Dec 31, 2024 | 80.75 Mn |
| Sep 30, 2024 | -27.79 Mn |
| Sep 30, 2024 | -27.79 Mn |
| Dec 31, 2023 | 51.64 Mn |
| Dec 31, 2023 | 51.64 Mn |
| Sep 30, 2023 | -15.36 Mn |
| Sep 30, 2023 | -15.36 Mn |
| Dec 31, 2022 | 239.63 Mn |
| Dec 31, 2022 | 239.63 Mn |
| Jun 30, 2022 | -30.30 Mn |
| Jun 30, 2022 | -30.30 Mn |
| Mar 31, 2022 | -29.95 Mn |
| Mar 31, 2022 | -29.95 Mn |
| Dec 31, 2021 | -54.59 Mn |
| Dec 31, 2021 | -54.59 Mn |
| Sep 30, 2021 | -44.02 Mn |
| Sep 30, 2021 | -44.02 Mn |
| Jun 30, 2021 | -41.92 Mn |
| Jun 30, 2021 | -41.92 Mn |